10x Genomics Files 8-K on Operations & Financial Condition
Ticker: TXG · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1770787
| Field | Detail |
|---|---|
| Company | 10x Genomics, Inc. (TXG) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: financial-condition, results-of-operations, 8-K
TL;DR
**TXG just dropped an 8-K on its financials, get ready for potential stock movement.**
AI Summary
10x Genomics, Inc. filed an 8-K on January 8, 2024, to report on its results of operations and financial condition. This filing, under SEC File Number 001-39035, indicates that the company is providing an update on its financial performance. For investors, this matters because it offers a timely glimpse into the company's health, potentially influencing stock price movements based on the disclosed financial results.
Why It Matters
This filing signals that 10x Genomics is updating the market on its financial performance, which is crucial for investors to assess the company's current health and future prospects.
Risk Assessment
Risk Level: medium — The risk level is medium because the filing itself doesn't contain specific financial figures, but it indicates that such information is being disclosed, which could lead to significant stock volatility depending on the actual results.
Analyst Insight
A smart investor would monitor for the actual financial results that this 8-K is likely preceding or announcing, as those specifics will dictate the true impact on 10x Genomics' stock (TXG).
Key Players & Entities
- 10x Genomics, Inc. (company) — the registrant filing the 8-K
- January 8, 2024 (date) — date of the earliest event reported
- 001-39035 (string) — SEC File Number for 10x Genomics, Inc.
- TXG (string) — trading symbol for 10x Genomics Class A common stock
- The Nasdaq Stock Market LLC (string) — exchange where TXG Class A common stock is registered
FAQ
What is the purpose of this 8-K filing by 10x Genomics, Inc.?
The 8-K filing by 10x Genomics, Inc. on January 8, 2024, is intended to report on the company's 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' as per the 'ITEM INFORMATION' section of the filing.
What is the trading symbol and the exchange where 10x Genomics, Inc.'s Class A common stock is registered?
10x Genomics, Inc.'s Class A common stock, with a par value of $0.00001 per share, trades under the symbol TXG and is registered on The Nasdaq Stock Market LLC, as stated in the 'Securities registered pursuant to Section 12(b) of the Act' section.
What is the state of incorporation for 10x Genomics, Inc. and its IRS Employer Identification Number?
10x Genomics, Inc. is incorporated in Delaware and its IRS Employer Identification No. is 45-5614458, according to the header information and the main body of the 8-K filing.
What is the business address and phone number of 10x Genomics, Inc.?
The business address for 10x Genomics, Inc. is 6230 Stoneridge Mall Road, Pleasanton, California 94588, and its business phone number is (925) 401-7300, as detailed in the 'BUSINESS ADDRESS' section of the filing.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 8, 2024, as explicitly stated under 'Date of Report (Date of earliest event reported): January 8, 2024'.
Filing Stats: 520 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-01-08 09:00:29
Key Financial Figures
- $0.00001 — tered Class A common stock, par value $0.00001 per share TXG The Nasdaq Stock Market
Filing Documents
- txg-20240108.htm (8-K) — 27KB
- ex-991_2024x01x08.htm (EX-99.1) — 15KB
- a10x_logoxhorizontalxfullc.jpg (GRAPHIC) — 152KB
- txg-20240108_g1.jpg (GRAPHIC) — 223KB
- 0001770787-24-000004.txt ( ) — 884KB
- txg-20240108.xsd (EX-101.SCH) — 2KB
- txg-20240108_lab.xml (EX-101.LAB) — 23KB
- txg-20240108_pre.xml (EX-101.PRE) — 12KB
- txg-20240108_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On January 8, 2024, 10x Genomics, Inc. (the "Company") issued a press release announcing the Company's preliminary fourth quarter and full year revenue for the period ended December 31, 2023. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished pursuant to Item 2.02 in this Current Report on Form 8-K and the press release attached as Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibits 99.1 Press Release dated January 8, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 10x Genomics, Inc. By: /s/ Eric S. Whitaker Name: Eric S. Whitaker Title: Chief Legal Officer Date: January 8, 2024